E3 Ubiquitin Ligase UBR5 Promotes Gemcitabine Resistance in Pancreatic Cancer by Inducing O-GlcNAcylation-Mediated EMT via Destabilization of OGA

Investigators reported that ubiquitin-protein ligase E3 module N-recognition 5 (UBR5) was a therapeutic target against gemcitabine (GEM) resistance. Further analysis revealed that UBR5 promoted GEM resistance in pancreatic cancer cells by enhancing O-GlcNAcylation-mediated epithelial-mesenchymal transition.